Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2010, Article ID 517198, 8 pages
http://dx.doi.org/10.1155/2010/517198
Research Article

Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents

1Department of Environmental Medicine and Public Health, Institute of Hygiene, University of Padua, Via loredan 18, 35151 Padua, Italy
2Global Clinical Research and Development, Novartis Vaccines & Diagnostics S.r.l., Via Fiorentina 1, 53100 Siena, Italy
3Local Health Unit n.13, Veneto Region, Via L. Mariutto, 76-30035 Mirano, Italy
4Department of Medicine and Public Health, Section of Hygiene and Preventive, Environmental and Occupational Medicine, University of Verona, Strada Le Grazie, 8-37134 Verona, Italy
5Department of Surgical and Gastroenterological Sciences, University of Padua, Via Giustiniani 2, 35100 Padua, Italy

Received 25 August 2009; Accepted 7 January 2010

Academic Editor: Jiri Mestecky

Copyright © 2010 Vincenzo Baldo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. W. Thompson, D. K. Shay, E. Weintraub et al., “Mortality associated with influenza and respiratory syncytial virus in the United States,” Journal of the American Medical Association, vol. 289, no. 2, pp. 179–186, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Ferrucci, J. M. Guralnik, M. Pahor, M. C. Corti, and R. J. Havlik, “Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled,” Journal of the American Medical Association, vol. 277, no. 9, pp. 728–734, 1997. View at Google Scholar · View at Scopus
  3. J. E. McElhaney, “The unmet need in the elderly: designing new influenza vaccines for older adults,” Vaccine, vol. 23, supplement 1, pp. S10–S25, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. Ch. Van Hoecke, V. Prikazsky, I. Uto, and C. Menschikowski, “Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients,” Gerontology, vol. 42, no. 4, pp. 190–198, 1996. View at Google Scholar · View at Scopus
  5. M. J. W. Sprenger, P. G. H. Mulder, W. E. P. Beyer, R. Van Strik, and N. Masurel, “Impact of influenza on mortality in relation to age and underlying disease, 1967–1989,” International Journal of Epidemiology, vol. 22, no. 2, pp. 334–340, 1993. View at Google Scholar · View at Scopus
  6. V. Baldo, T. Menegon, C. Bonello, A. Floreani, and R. Trivello, “Comparison of three different influenza vaccines in institutionalised elderly,” Vaccine, vol. 19, no. 25-26, pp. 3472–3475, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. T. A. Reichert, L. Simonsen, A. Sharma, S. A. Pardo, D. S. Fedson, and M. A. Miller, “Influenza and the winter increase in mortality in the United States, 1959–1999,” American Journal of Epidemiology, vol. 160, no. 5, pp. 492–502, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. W. W. Thompson, D. K. Shay, E. Weintraub et al., “Influenza-associated hospitalizations in the United States,” Journal of the American Medical Association, vol. 292, no. 11, pp. 1333–1340, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. WHO 2003: Fact sheet no. 211., July 2009, http://www.who.int/mediacentre/factsheets/fs211/en/Web.
  10. K. L. Nichol, “The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines,” Vaccine, vol. 21, no. 16, pp. 1769–1775, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Herndler-Brandstetter, S. Schwaiger, E. Veel et al., “CD25-expressing CD8+ T cells are potent memory cells in old age,” Journal of Immunology, vol. 175, no. 3, pp. 1566–1574, 2005. View at Google Scholar · View at Scopus
  12. L. Lazuardi, B. Jenewein, A. M. Wolf, G. Pfister, A. Tzankov, and B. Grubeck-Loebenstein, “Age-related loss of naive T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes,” Immunology, vol. 114, no. 1, pp. 37–43, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Weinberger, D. Herndler-Brandstetter, A. Schwanninger, D. Weiskopf, and B. Grubeck-Loebenstein, “Biology of immune responses to vaccines in elderly persons,” Clinical Infectious Diseases, vol. 46, no. 7, pp. 1078–1084, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. N. J. Cox and K. Subbarao, “Global epidemiology of influenza: past and present,” Annual Review of Medicine, vol. 51, pp. 407–421, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. A. S. Monto, “Epidemiology and virology of influenza illness,” American Journal of Managed Care, vol. 6, no. 5, pp. S255–S264, 2000. View at Google Scholar · View at Scopus
  16. J. Nordin, J. Mullooly, S. Poblete et al., “Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans,” Journal of Infectious Diseases, vol. 184, no. 6, pp. 665–670, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Treanor, “Influenza caccine—outmaneuvering antigenic shift and drift,” New England Journal of Medicine, vol. 350, no. 3, pp. 218–220, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. J. C. de Jong, W. E. P. Beyer, A. M. Palache, G. F. Rimmelzwaan, and A. D. M. E. Osterhaus, “Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly,” Journal of Medical Virology, vol. 61, no. 1, pp. 94–99, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Ansaldi, S. Bacilieri, F. Banfi et al., “Neutralizing and hemagglutination-inhibiting activities of antibodies elicited by the 2004-2005 influenza vaccine against drifted viruses,” Clinical and Vaccine Immunology, vol. 13, no. 1, pp. 162–164, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. G. D. Giudice, A. K. Hilbert, R. Bugarini et al., “An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine,” Vaccine, vol. 24, no. 16, pp. 3063–3065, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Kojimahara, A. Maeda, T. Kase, and N. Yamaguchi, “Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine,” Vaccine, vol. 24, no. 33-34, pp. 5966–5969, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Ansaldi, S. Bacilieri, P. Durando et al., “Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses,” Vaccine, vol. 26, no. 12, pp. 1525–1529, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Menegon, V. Baldo, C. Bonello, D. Dalla Costa, A. Di Tommaso, and R. Trivello, “Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population,” European Journal of Epidemiology, vol. 15, no. 6, pp. 573–576, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Kanegae, S. Sugita, A. Endo et al., “Evolutionary pattern of the hemagglutinin gene of influenza B viruses isolated in Japan: cocirculating lineages in the same epidemic season,” Journal of Virology, vol. 64, no. 6, pp. 2860–2865, 1990. View at Google Scholar · View at Scopus
  25. K. Tamura, J. Dudley, M. Nei, and S. Kumar, “MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0,” Molecular Biology and Evolution, vol. 24, no. 8, pp. 1596–1599, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. W. E. P. Beyer, A. M. Palache, G. Luchters, J. Nauta, and A. D. M. E. Osterhaus, “Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?” Virus Research, vol. 103, no. 1-2, pp. 125–132, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. T. R. Cate, “Clinical manifestations and consequences of influenza,” American Journal of Medicine, vol. 82, no. 6, pp. 15–19, 1987. View at Google Scholar · View at Scopus
  28. J. J. P. Nauta, W. E. P. Beyer, and A. D. M. E. Osterhaus, “On the relationship between mean antibody level, seroprotection and clinical protection from influenza,” Biologicals, vol. 37, no. 4, pp. 216–221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. A. S. Monto and A. P. Kendal, “Effect of neuraminidase antibody on Hong Kong influenza,” The Lancet, vol. 1, no. 7804, pp. 623–625, 1973. View at Google Scholar · View at Scopus
  30. B. D. Forrest, M. W. Pride, A. J. Dunning et al., “Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children,” Clinical and Vaccine Immunology, vol. 15, no. 7, pp. 1042–1053, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. E. D. Kilbourne, “Inactivated influenza vaccines,” in Vaccines, A. Plotkin and E. A. Mortimer, Eds., pp. 565–581, Saunders, Philadelphia, Pa, USA, 1994. View at Google Scholar
  32. M. L. Clements and I. Stephens, “New and improved vaccines against influenza,” in New Generation Vaccines, pp. 545–570, Marcel Dekker, New York, NY, USA, 2nd edition, 1997. View at Google Scholar